Ibrutinib is a drug for the treatment of rare diseases. It has been approved for the treatment of adults with chronic lymphocytic leukaemia (CLL) or with relapsed or refractory mantle cell lymphoma ...
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLL Sonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in ...
Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated ...
BeOne Medicines Ltd. (“BeOne”) (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U ...
Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche deal—review the catalysts, ...
Panelists discuss the future of Bruton tyrosine kinase (BTK) inhibitor therapies, considering emerging treatments, regulatory changes, evolving cost dynamics, and the current unmet needs in chronic ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted ...
Please provide your email address to receive an email when new articles are posted on . Tandem-target CAR-T produced a response in all participants with relapsed or refractory mantle cell lymphoma in ...
The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...
Lupeng Pharma’s fourth-generation BTK inhibitor rocbrutinib approved in China for relapsed or refractory mantle cell lymphoma: Guangzhou, China Friday, June 5, 2026, 16:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results